Chenxin Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chenxin Zhou has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Dong Wang
Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing
2 shared publicationsJian Ge
Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing
2 shared publications- Rui Zhang
Beijing Children’s Hospital, Capital Medical University, Beijing, China
2 shared publications Tianyou Wang
Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing
2 shared publicationsZishi Fang
Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing
2 shared publicationsBaosheng Sun
Beijing Children’s Hospital, Capital Medical University , National Center for Children’s Health, Beijing
1 shared publication
Latest Publications
- Open Access
- 29 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Watchful Waiting in Children with Unifocal Osseous Langerhans Cell Histiocytosis
Background: Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplasm most commonly involving bone. However, data on single-system, single-site LCH (SS-s-LCH), particularly with unifocal bone disease, remain limited. Management strategies for unifocal osseous LCH vary globally, and the safety of a watchful-waiting approach is not well-defined. This study aimed to evaluate whether patients with osseous SS-s-LCH can be managed with observation alone without compromising long-term outcomes. Methods: In this retrospective, multicenter study, we enrolled children with biopsy-proven osseous SS-s-LCH from seven centers in the Chinese Children’s Histiocytosis Group, excluding those with central nervous system (CNS)-risk bone lesions. The primary endpoint was 3-year event-free survival (EFS). Events were defined as disease progression or relapse. Results: The cohort included 134 patients with a median follow-up of 36.0 months. Involved sites were cranial bones (n = 37), vertebrae (n = 33), and other bones (n = 64). At final follow-up, 16 patients had experienced an event, yielding a 3-year EFS of 88.1% (95% CI: 81.5–92.5%). Events included new lesions (n = 14) and primary lesion expansion (n = 2), with 93.8% (15/16) occurring within the first 12 months after diagnosis. EFS did not differ significantly by involved site or mutation status. However, patients staged by PET-CT at diagnosis had a significantly higher 3-year EFS (97.6%) than those staged by conventional imaging (83.7%) (p < 0.05). Long-term quality of life was satisfactory in all assessed patients. Conclusion: Watchful waiting is a safe and effective management strategy for children with unifocal osseous SS-s-LCH. Initial staging with PET-CT may be associated with superior event-free survival, highlighting its potential value in refining risk assessment.
- 29 April 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Open AccessWatchful Waiting in Children with Unifocal Osseous Langerhans Cell Histiocytosis
Background: Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplasm most commonly involving bone. However, data on single-system, single-site LCH (SS-s-LCH), particularly with unifocal bone disease, remain limited. Management strategies for unifocal osseous LCH vary globally, and the safety of a watchful-waiting approach is not well-defined. This study aimed to evaluate whether patients with osseous SS-s-LCH can be managed with observation alone without compromising long-term outcomes. Methods: In this retrospective, multicenter study, we enrolled children with biopsy-proven osseous SS-s-LCH from seven centers in the Chinese Children’s Histiocytosis Group, excluding those with central nervous system (CNS)-risk bone lesions. The primary endpoint was 3-year event-free survival (EFS). Events were defined as disease progression or relapse. Results: The cohort included 134 patients with a median follow-up of 36.0 months. Involved sites were cranial bones (n = 37), vertebrae (n = 33), and other bones (n = 64). At final follow-up, 16 patients had experienced an event, yielding a 3-year EFS of 88.1% (95% CI: 81.5–92.5%). Events included new lesions (n = 14) and primary lesion expansion (n = 2), with 93.8% (15/16) occurring within the first 12 months after diagnosis. EFS did not differ significantly by involved site or mutation status. However, patients staged by PET-CT at diagnosis had a significantly higher 3-year EFS (97.6%) than those staged by conventional imaging (83.7%) (p < 0.05). Long-term quality of life was satisfactory in all assessed patients. Conclusion: Watchful waiting is a safe and effective management strategy for children with unifocal osseous SS-s-LCH. Initial staging with PET-CT may be associated with superior event-free survival, highlighting its potential value in refining risk assessment.
- 15 July 2025
- Published by Wiley in British Journal of Haematology
Efficacy and safety of ruxolitinib‐based regimen in the treatment of paediatric Epstein–Barr virus‐associated haemophagocytic lymphohistiocytosis
Summary: Ruxolitinib (RUX) has demonstrated efficacy in haemophagocytic lymphohistiocytosis (HLH) patients, but large cohort studies regarding its clinical application in children with Epstein–Barr virus‐associated HLH (EBV‐HLH) remain scarce. This retrospective study analysed the efficacy and safety of RUX‐based regimen (n = 53) and compared it with adjusted HLH‐94 chemotherapy (n = 42) in the treatment of paediatric EBV‐HLH. The patients treated with the RUX‐based regimen received RUX monotherapy as front‐line therapy. Additional methylprednisolone and etoposide would be added in sequence if the response was unsatisfactory. At 8 weeks of therapy, the overall response rate of the RUX group was comparable to that of the traditional chemotherapy group (84.9% vs. 76.2%, p = 0.282), with a 12‐month survival rate of 92.2% (95% CI: 80.6–97.0) and 87.6% (95% CI: 72.1–94.5) (p = 0.595). In the RUX group, 56.6% of patients achieved sustained remission without requiring etoposide during a median follow‐up of 17.2 months. Among these patients, 93.3% had primary EBV infection. The RUX‐based regimen was well‐tolerated, exhibiting significantly lower incidence of myelosuppression and secondary infection than adjusted HLH‐94 chemotherapy (35.8% vs. 95.2%, p < 0.001; 28.3% vs. 59.5%, p = 0.002). Overall, our preliminary results indicated that EBV‐HLH children treated with the RUX‐based regimen demonstrated favourable efficacy while significantly reducing treatment‐related adverse events.
- 15 July 2025
- Published by Wiley in British Journal of Haematology
Efficacy and safety of ruxolitinib‐based regimen in the treatment of paediatric Epstein–Barr virus‐associated haemophagocytic lymphohistiocytosis
Summary: Ruxolitinib (RUX) has demonstrated efficacy in haemophagocytic lymphohistiocytosis (HLH) patients, but large cohort studies regarding its clinical application in children with Epstein–Barr virus‐associated HLH (EBV‐HLH) remain scarce. This retrospective study analysed the efficacy and safety of RUX‐based regimen (n = 53) and compared it with adjusted HLH‐94 chemotherapy (n = 42) in the treatment of paediatric EBV‐HLH. The patients treated with the RUX‐based regimen received RUX monotherapy as front‐line therapy. Additional methylprednisolone and etoposide would be added in sequence if the response was unsatisfactory. At 8 weeks of therapy, the overall response rate of the RUX group was comparable to that of the traditional chemotherapy group (84.9% vs. 76.2%, p = 0.282), with a 12‐month survival rate of 92.2% (95% CI: 80.6–97.0) and 87.6% (95% CI: 72.1–94.5) (p = 0.595). In the RUX group, 56.6% of patients achieved sustained remission without requiring etoposide during a median follow‐up of 17.2 months. Among these patients, 93.3% had primary EBV infection. The RUX‐based regimen was well‐tolerated, exhibiting significantly lower incidence of myelosuppression and secondary infection than adjusted HLH‐94 chemotherapy (35.8% vs. 95.2%, p < 0.001; 28.3% vs. 59.5%, p = 0.002). Overall, our preliminary results indicated that EBV‐HLH children treated with the RUX‐based regimen demonstrated favourable efficacy while significantly reducing treatment‐related adverse events.